0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Octreotide Treatment of Acromegaly

      Hormone Research in Paediatrics

      S. Karger AG

      Sandostatin, Acromegaly, Octreotide

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The experience of St Bartholomew’s Hospital in the treatment of acromegaly with octreotide is presented. When administered intravenously and subcutaneously, octreotide had a longer circulating half-life than natural somatostatin. Subcutaneous octreotide in a range of doses (50-400 µg) caused a very similar degree of growth hormone (GH) suppression, but the duration of suppression increased with size of dose. A dose of 100 µg octreotide 8-hourly provided very good suppression of GH in acromegalic patients; occasional nocturnal escapes may be a problem of inadequate dosage. Long-term octreotide treatment in 14 patients reduced GH to below 20 mU/1 and only 1 case was apparently unresponsive. No serious side effects have so far been seen. Octreotide antibodies have been detected in 1 patient unresponsive to octreotide infusion. Gallstones have been found in 6 of 14 patients.

          Related collections

          Author and article information

          Journal
          HRE
          Horm Res Paediatr
          10.1159/issn.1663-2818
          Hormone Research in Paediatrics
          S. Karger AG
          978-3-8055-5207-3
          978-3-318-01978-0
          1663-2818
          1663-2826
          1990
          1990
          02 December 2008
          : 33
          : Suppl 1
          : 1-6
          Affiliations
          Department of Endocrinology, St Bartholomew’s Hospital Medical College, London, UK
          Article
          181547 Horm Res 1990;33:1–6
          10.1159/000181547
          2358293
          © 1990 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 6
          Categories
          Acromegaly

          Comments

          Comment on this article